In a 5 July warning letter to Outset Medical, the US Food and Drug Administration cited two concerns with the company’s Tablo Hemodialysis System, which is designed to treat kidney disease at home.
The agency’s first concern relates to materials on the company’s website that promote continuous renal replacement therapy (CRRT), a slower type of dialysis that puts less stress on the heart....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?